Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.40 |
| ▸ | CHRNG | P07510 | 2/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRND | Q07001 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22654437 | 0.87 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL21236191 | 0.87 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL22654456 | 0.87 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL2732428 | 0.83 | SLC6A3 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2732429 | 0.83 | SLC6A3 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18198499 | 0.83 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15517006 | 0.80 | SLC6A3 (0.42) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1808477 | 0.79 | HSD17B1 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3545656 | 0.79 | HSD17B1 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL28111403 | 0.78 | SLC6A2 (0.42) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-07-16 | — | — | US | disclosed |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-15 | — | — | US | disclosed |
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | SLC6A4 2957/4885SLC6A3 4067/4885SLC6A2 4118/4885 |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | SLC6A4 2957/4885SLC6A3 4067/4885SLC6A2 4118/4885 |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | SLC6A4 2957/4885SLC6A3 4067/4885SLC6A2 4118/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | SLC6A4 2957/4885SLC6A3 4067/4885SLC6A2 4118/4885 |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | SLC6A4 2957/4885SLC6A3 4067/4885SLC6A2 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.